Michael H Barnett

List of Publications by Year
in descending order

136 papers	6,931 citations	94269 37 h-index	64668 79 g-index
142 all docs	142 docs citations	142 times ranked	7129 citing authors

#	Article	IF	Citations
1	Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. journal of applied laboratory medicine, The, 2022, 7, 12-25.	0.6	7
2	NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 2022, 269, 836-845.	1.8	5
3	Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter. Multiple Sclerosis Journal, 2022, 28, 697-706.	1.4	7
4	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. Multiple Sclerosis Journal, 2022, 28, 958-969.	1.4	6
5	A randomized controlled trial of a web-based mindfulness programme for people with MS with and without a history of recurrent depression. Multiple Sclerosis Journal, 2022, 28, 1392-1401.	1.4	7
6	Multiple Sclerosis Lesion Analysis in Brain Magnetic Resonance Images: Techniques and Clinical Applications. IEEE Journal of Biomedical and Health Informatics, 2022, 26, 2680-2692.	3.9	18
7	The expansion and severity of chronic MS lesions follows a periventricular gradient. Multiple Sclerosis Journal, 2022, 28, 1504-1514.	1.4	9
8	Diagnosis, differential diagnosis and misdiagnosis of Susac syndrome. European Journal of Neurology, 2022, 29, 1771-1781.	1.7	16
9	Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	5
10	Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology, 2022, 18, 289-306.	4.9	27
11	FOD-Net: A deep learning method for fiber orientation distribution angular super resolution. Medical Image Analysis, 2022, 79, 102431.	7.0	9
12	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 978-985.	0.9	17
13	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.5	12
14	MRI and laboratory monitoring of disease-modifying therapy efficacy and risks. Current Opinion in Neurology, 2022, 35, 278-285.	1.8	5
15	Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data. BMJ Neurology Open, 2022, 4, e000315.	0.7	3
16	Expansion of chronic lesions is linked to disease progression in relapsingâ€“remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2021, 27, 1533-1542.	1.4	29
17	Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis. Journal of Neurology, 2021, 268, 2379-2389.	1.8	26
18	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11

#	Article	IF	Citations
19	Overlapping central and peripheral nervous system syndromes in MOG antibodyâ€“associated disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	58
20	Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis. PLoS ONE, 2021, 16, e0244766.	1.1	7
21	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. NeuroImage: Clinical, 2021, 32, 102802.	1.4	5
22	Interferon-Î² Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	8
23	Development of a Web-Based Mindfulness Program for People With Multiple Sclerosis: Qualitative Co-Design Study. Journal of Medical Internet Research, 2021, 23, e19309.	2.1	5
24	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.5	41
25	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Multiple Sclerosis and Related Disorders, 2021, 50, 102849.	0.9	7
26	Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1319-1324.	0.9	6
27	Thinking fast not slow: a fast-acting, high-titre acquired factor VIII inhibitor. Pathology, 2021, , .	0.3	1
28	Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1033-1043.	0.9	26
29	Remyelination Trials. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	10
30	Association Between Cognitive Trajectories and Disability Progression in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 2021, 97, e2020-e2031.	1.5	7
31	MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis. Frontiers in Neurology, 2021, 12, 722237.	1.1	8
32	Latency of Multifocal Visual Evoked Potential in Multiple Sclerosis: A Visual Pathway Biomarker for Clinical Trials of Remyelinating Therapies. Journal of Clinical Neurophysiology, 2021, 38, 186-191.	0.9	8
33	Targeting B Cells to Modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	37
34	Targeting B cells to modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	30
35	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.5	54
36	Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study). JMIR Research Protocols, 2021, 10, e24969.	0.5	4

#	Article	IF	Citations
37	Response to treatment in NMOSD: the Australasian experience. Multiple Sclerosis and Related Disorders, 2021, 58, 103408.	0.9	0
38	Title is missing!. , 2021, 16, e0244766.		0
39	Title is missing!. , 2021, 16, e0244766.		0
40	Title is missing!. , 2021, 16, e0244766.		0
41	Title is missing!. , 2021, 16, e0244766.		0
42	Title is missing!. , 2021, 16, e0244766.		0
43	Title is missing!. , 2021, 16, e0244766.		0
44	Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment. Molecular Neurobiology, 2020, 57, 1245-1258.	1.9	35
45	Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521732095735.	0.5	6
46	Neurological manifestations of severe acute respiratory syndrome coronavirus 2â€”a controversy â€˜gone viralâ€™. Brain Communications, 2020, 2, fcaa149.	1.5	7
47	COVID-19 and the Sacrificial International Order. International Organization, 2020, 74, E128-E147.	3.6	18
48	Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules. Multiple Sclerosis and Related Disorders, 2020, 43, 102175.	0.9	7
49	Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry. Frontiers in Immunology, 2020, 11, 119.	2.2	7
50	Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation. Frontiers in Neurology, 2020, 11, 537.	1.1	27
51	The clinical profile of NMOSD in Australia and New Zealand. Journal of Neurology, 2020, 267, 1431-1443.	1.8	17
52	Alemtuzumab: Rare serious adverse events of a high-efficacy drug. Multiple Sclerosis Journal, 2020, 26, 737-740.	1.4	14
53	Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	21
54	Masked Multi-Task Network for Case-Level Intracranial Hemorrhage Classification in Brain CT Volumes. Lecture Notes in Computer Science, 2020, , 145-154.	1.0	4

#	Article	IF	Citations
55	Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study. Multiple Sclerosis Journal, 2019, 25, 1124-1131.	1.4	7
56	Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Ophthalmology, 2019, 126, 445-453.	2.5	69
57	Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 104-107.	0.9	7
58	Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. Journal of Neuroimaging, 2019, 29, 615-623.	1.0	8
59	Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	3.1	22
60	AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. Frontiers in Neurology, 2019, 10, 1028.	1.1	56
61	Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. Acta Neuropathologica Communications, 2019, 7, 145.	2.4	71
62	The spectrum of immune-mediated and inflammatory lesions of the brainstem. Neurology, 2019, 93, 390-405.	1.5	22
63	Demyelination precedes axonal loss in the transneuronal spread of human neurodegenerative disease. Brain, 2019, 142, 426-442.	3.7	78
64	The evaluation of an online mindfulness program for people with multiple sclerosis: study protocol. BMC Neurology, 2019, 19, 129.	0.8	12
65	The electrophysiological assessment of visual function in Multiple Sclerosis. Clinical Neurophysiology Practice, 2019, 4, 90-96.	0.6	30
66	Evidence of MÃ¼ller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin Gâ€“Positive Neuromyelitis Optica Spectrum Disorder. Ophthalmology, 2019, 126, 801-810.	2.5	54
67	Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes). Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 882-894.	0.9	23
68	Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983657.	1.5	83
69	039â€…Estimating the health and economic burden of investigating tumefactive demyelination compared to conventional multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A13.3-A14.	0.9	0
70	111â€…Recurrent headaches with psychosis, CSF lymphocytosis, vessel beading and papilloedema-autoimmune/viral encephalitis with vasculopathy or unusual presentation of reversible cerebral vasoconstriction syndrome (RCVS)?. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A36.1-A36.	0.9	0
71	091â€…Cerebellar oedema in fulminant adult leigh syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A29.2-A29.	0.9	0
72	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	5.8	87

#	Article	IF	Citations
73	Imaging the multiple sclerosis lesion: insights into pathogenesis, progression and repair. Current Opinion in Neurology, 2019, 32, 338-345.	1.8	10
74	Core temperature is not elevated at rest in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 62-67.	0.9	1
75	Forearmâ€predominant parainfectious myositis. Muscle and Nerve, 2019, 59, E7-E10.	1.0	0
76	Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 514-521.	0.9	66
77	We should focus more on finding therapeutic targets for the non-inflammatory damage in MS â€“ Yes. Multiple Sclerosis Journal, 2018, 24, 1272-1274.	1.4	1
78	Progressive inner nuclear layer dysfunction in non-optic neuritis eyes in MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e427.	3.1	28
79	Evidence of progressive tissue loss in the core of chronic MS lesions: A longitudinal DTI study. NeuroImage: Clinical, 2018, 17, 1028-1035.	1.4	46
80	The evolution of â€œNo Evidence of Disease Activityâ€•in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 20, 231-238.	0.9	48
81	Cladribine versus fingolimod, natalizumab and interferon Î² for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	1.4	36
82	Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 127-137.	0.9	422
83	Cold Water Ingestion Improves Exercise Tolerance of Heat-Sensitive People with MS. Medicine and Science in Sports and Exercise, 2018, 50, 643-648.	0.2	18
84	Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. Npj Precision Oncology, 2018, 2, 28.	2.3	116
85	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	1.4	8
86	Diffusivity in the core of chronic multiple sclerosis lesions. PLoS ONE, 2018, 13, e0194142.	1.1	8
87	113â€…Rituximab and maintenance mycophenolate mofetil for treatment of refractory ANTI-N-METHYL-D-ASPARTATE-receptor (NMDAR) encephalitis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A44.3-A45.	0.9	2
88	White matter tract-specific quantitative analysis in multiple sclerosis: Comparison of optic radiation reconstruction techniques. PLoS ONE, 2018, 13, e0191131.	1.1	9
89	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	1.4	30
90	Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology, 2017, 88, 1004-1006.	1.5	30

#	Article	IF	Citations
91	Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 632-638.	0.9	108
92	Maternal autoimmunity: risk of neurodevelopmental and neuropsychiatric outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 713-714.	0.9	0
93	MRI FLAIR lesion segmentation in multiple sclerosis: Does automated segmentation hold up with manual annotation?. NeuroImage: Clinical, 2017, 13, 264-270.	1.4	82
94	Exosomal microRNA signatures in multiple sclerosis reflect disease status. Scientific Reports, 2017, 7, 14293.	1.6	196
95	Vestibulo-ocular reflex deficits with medial longitudinal fasciculus lesions. Journal of Neurology, 2017, 264, 2119-2129.	1.8	22
96	Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. , 2016, 57, 2311.		62
97	Two Time Point MS Lesion Segmentation in Brain MRI: An Expectation-Maximization Framework. Frontiers in Neuroscience, 2016, 10, 576.	1.4	32
98	Progressive Injury in Chronic Multiple Sclerosis Lesions Is Gender-Specific: A DTI Study. PLoS ONE, 2016, 11, e0149245.	1.1	13
99	Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases. Current Opinion in Neurology, 2016, 29, 213-221.	1.8	22
100	Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurology, The, 2016, 15, 967-981.	4.9	121
101	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	3.7	281
102	Automated brain volumetrics in multiple sclerosis: a step closer to clinical application. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 754-757.	0.9	47
103	Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 2016, 16, 777-793.	1.4	126
104	Diffusivity in multiple sclerosis lesions: At the cutting edge?. NeuroImage: Clinical, 2016, 12, 219-226.	1.4	17
105	Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis. Neurology, 2016, 87, 2595-2597.	1.5	10
106	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1133-1137.	0.9	76
107	Acute bulbar, neck and limb weakness with monospecific antiâ€GT1a antibody: A rare localized subtype of Guillainâ€BarrÃ© sydnrome. Muscle and Nerve, 2016, 53, 143-146.	1.0	2
108	Migration and multiple sclerosis in immigrants from United Kingdom and Ireland to Australia: a reassessment. III: risk of multiple sclerosis in UKI immigrants and Australian-born in Hobart, Tasmania. Journal of Neurology, 2016, 263, 792-798.	1.8	11

#	Article	IF	Citations
109	Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients. Multiple Sclerosis Journal, 2016, 22, 1883-1887.	1.4	27
110	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	1.4	34
111	Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 470-482.	1.4	284
112	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	1.7	57
113	Tabletâ€based screening improves continence management in multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 679-687.	1.7	10
114	Decoding Diffusivity in Multiple Sclerosis: Analysis of Optic Radiation Lesional and Non-Lesional White Matter. PLoS ONE, 2015, 10, e0122114.	1.1	52
115	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	2.8	143
116	Distinguishing Susacâ€™s syndrome from multiple sclerosis. Journal of Neurology, 2015, 262, 1613-1621.	1.8	34
117	Axonal conduction in multiple sclerosis: A combined magnetic resonance imaging and electrophysiological study of the medial longitudinal fasciculus. Multiple Sclerosis Journal, 2015, 21, 905-915.	1.4	12
118	The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, jnnp-2014-309649.	0.9	51
119	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	3.7	162
120	BalÃ³'s concentric sclerosis and tumefactive demyelination: A shared immunopathogenesis?. Journal of the Neurological Sciences, 2015, 348, 279-281.	0.3	16
121	Brain histopathology in three cases of Susac's syndrome: implications for lesion pathogenesis and treatment: FigureÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 582-584.	0.9	54
122	Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e40.	3.1	192
123	Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1511-1522.	1.4	73
124	Progressive Neuropsychiatric Symptoms and Motor Impairment. JAMA Neurology, 2014, 71, 794.	4.5	3
125	Latency of Multifocal Visual Evoked Potentials in Nonoptic Neuritis Eyes of Multiple Sclerosis Patients Associated With Optic Radiation Lesions. , 2014, 55, 3758.		46
126	Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014, 82, 1204-1211.	1.5	138

#	Article	IF	Citations
127	Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. Neurology, 2014, 82, 2165-2172.	1.5	99
128	Brain Volumetrics, Regional Cortical Thickness and Radiographic Findings in Adults with Cyanotic Congenital Heart Disease. NeuroImage: Clinical, 2014, 4, 319-325.	1.4	34
129	Molecular Pathogenesis of Neuromyelitis Optica. International Journal of Molecular Sciences, 2012, 13, 12970-12993.	1.8	54
130	Neuromyelitis optica. Current Opinion in Neurology, 2012, 25, 215-220.	1.8	27
131	Blurred vision and pain in the eye. Medical Journal of Australia, 2011, 195, 329-332.	0.8	2
132	Spinal nerve root hypertrophy in chronic ataxic neuropathy with antiglycolipid IgM antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 97-97.	0.9	4
133	Immunoglobulins and complement in postmortem multiple sclerosis tissue. Annals of Neurology, 2009, 65, 32-46.	2.8	129
134	Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Annals of Neurology, 2009, 66, 739-753.	2.8	335
135	Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Annals of Neurology, 2004, 55, 458-468.	2.8	1,042
136	Immunopathology of secondary-progressive multiple sclerosis. Annals of Neurology, 2001, 50, 646-657.	2.8	371